<DOC>
	<DOCNO>NCT02475382</DOCNO>
	<brief_summary>The purpose study provide treatment nivolumab , fully human monoclonal antibody , subject relapse treatment minimum 1 prior systemic treatment advance metastatic squamous ( Sq ) non-squamous ( non-Sq ) non-small cell lung cancer ( NSCLC ) , Stage IIIB/IV whose physician believe nivolumab treatment appropriate .</brief_summary>
	<brief_title>Expanded Access Program With Nivolumab Therapy Treatment Advanced/Metastatic SqNSCLC Non-SqNSCLC After One Prior Systemic Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Sq NonSq NSCLC , Stage IIIb/IV ( histologically cytologically confirm ) Relapsed 1 prior platinumbased systemic treatment Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 2 CNS metastasis must treat returned baseline least 2 week first dose nivolumab steroid use stable decrease dose &lt; 10 mg prednisone equivalent Prior chemotherapy , Tyrosine Kinase Inhibitor ( TKI ) therapy Immunotherapy ( tumor vaccine , cytokine growth factor control cancer ) must complete least 2 week first nivolumab dose CNS metastasis ( untreated and/or symptomatic ) Carcinomatous meningitis ECOG Performance status &gt; 3 Corticosteroids &gt; 10 mg prednisolone/day ( equivalent ) Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCT137 antiCTLA antibody , include ipilimumab drug specifically target T cell costimulation checkpoint pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>